LifeSignals receives CE Mark Approval for LifeSignals LX1550E Multiparameter Remote Monitoring Platform
Enables healthtech partners to deliver continuous remote patient vital signs monitoring within hospital and home settings.
FREMONT, Calif., May 19, 2021 /CNW/ -- LifeSignals Inc., today announced the CE (Conformité Européene) Mark for the LifeSignals LX1550E Multiparameter Remote Monitoring Platform – which can be used by clinicians for the continuous collection of physiological data of patients at home and in healthcare settings.
The single-use, wearable medical biosensor, records Electrocardiography (2-channel ECG), Heart Rate, Respiration rate, Skin Temperature and Body Posture data for up to five days. The encrypted physiological data can then be transmitted with high reliability from the LifeSignals Biosensor, via the Relay App to a secure cloud-based platform. Clinicians and Care Providers can access the cloud-based LifeSignals Remote Monitoring Dashboard to view patient physiological data and manage vital sign alert settings.
The LifeSignals Remote Monitoring Platform is designed to enable healthtech companies to rapidly enhance their product and service portfolios to provide vital sign monitoring to the widest possible patient base, from any location. The interoperable platform can be tailored with ready-to-deploy software development kit APIs and is suitable for large scale implementation.
"COVID-19 has accelerated the adoption of remote patient monitoring globally," says Steve Jones, Business Development Director, Europe. "This regulatory approval for our Multiparameter Platform is a significant breakthrough and will enable our Partners to bring to market affordable and scalable remote monitoring products and solutions".
About LifeSignals, Inc.
LifeSignals is the leader in Wearable Medical Biosensors. LifeSignals provides a flexible biosensor platform to enable Partners to create clinical-grade, remote monitoring products and solutions. LifeSignals biosensors are multi-parameter, low cost and disposable, and deliver clinical-grade accuracy that is reliable and secure. Based in Silicon Valley, and offices in New York, London, Ireland, Singapore and India, LifeSignals is a global venture capital backed company, enabled by equity investments from Flex, Uniquest, Dreamtech, Renew Group, Seraph Group, XSeed Capital, and Reddy Capital. Further information can be found at www.lifesignals.com.
Contacts:
LifeSignals
Kim Ramessa
Marketing Director
LifeSignals Europe Ltd
M: +44 (0) 7425 316305
E: [email protected]
Media
Richard Hayhurst
RHApr
M: +44 (0) 7711 821527
E: [email protected]
SOURCE Life Signals Inc.
Share this article